JUser: :_load: Unable to load user with ID: 221


Thursday, 23 July 2015 23:07

Cochrane Library: Erythropoiesis-stimulating agents for anemia (new evidence summary) Featured

Rate this item
(2 votes)

Cochrane Library: Erythropoiesis-stimulating agents for anemia



Anemia affects nearly all adults with advanced kidney disease and is linked to fatigue, breathlessness, impaired quality of life and physical function, and shorter survival. ESA treatment aims to improve anemia-related symptoms and minimize treatment-related cardiovascular events. Several ESA classes are available for anemia treatment (epoetin alfa, epoetin beta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta as well as biosimilar ESAs) but whether these drugs have differing benefits and harms is uncertain. This Cochrane review directly compares available ESAs for treatment of anemia among adults with chronic kidney disease.



Suetonia Palmer

Suetonia is a nephrologist based at the University of Otago, Christchurch in New Zealand, and who trained in New Zealand and the USA. She is an Editor for Cochrane Kidney and Transplant.


Giovanni Strippoli

Giovanni is a nephrologist based at the University of Bari in Italy, who also trained at the Sydney School of Public Health, Australia. He is an Editor for Cochrane Kidney and Transplant and the journal Nephrology, Dialysis and Transplantation.


Copyright© 2015 Cochrane Kidney and Transplant. Published by John Wiley & Sons, Ltd.


Additional Info

  • Language: English
  • Contains Audio: Yes
  • Content Type: Presentations
  • Source: Cochrane
  • Year: 2015
  • Members Only: No
Read 10875 times Last modified on Thursday, 28 January 2016 14:12

compact blue

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact